Latest Breaking News On - Jill hopkins - Page 8 : comparemela.com

NOVARTIS AG CHF0.50(REGD) Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept In KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in diabetic macular edema (DME) patients 1 More patients treated with Beovu 6 mg experienced fluid (IRF/SRF) resolution at week 32 and week 52 versus aflibercept; fluid is a key marker of disease activity in DME

United kingdomUnited statesIsabella zinckEylea tarrytownThomas hungerbuehlerDavidm brownAmy wolfSamir shahJill hopkinsJulie masowBeovu baselSloan simpsonNovartis division communicationsNovartis external communicationsNational eye instituteNational health insurance pricing